Navigation Links
China Yongxin Pharmaceuticals Inc. Announces Second Quarter 2009 Financial Results

CHANGCHUN, China and LOS ANGELES, Oct. 14 /PRNewswire-Asia/ -- China Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: CYXN; "China Yongxin Pharmaceuticals" or "the Company"), a leading manufacturer, distributor and retailer of pharmaceuticals in Northeastern China, today announced its unaudited financial results for the second quarter of 2009 which ended June 30, 2009.

Revenues for the second quarter of 2009 were essentially flat at approximately $14.6 million compared to the second quarter of 2008, with a marginal increase due to an increase in revenue from its retail drug stores offset by a decrease in volume from its pharmaceutical wholesale business. Revenues from retail drug stores were $6.0 million, compared to $5.8 million for the same period in 2008, which included a 10.9% increase for existing same store sales. A broader product portfolio, in addition to increased marketing activities, contributed to the growth. During the quarter, the Company launched one new chain drug store in Tianjin.

"We believe our business during the first half of 2009 was impacted by customers waiting for specifics on the new healthcare reform plan. On August 18 the Chinese government issued China's Essential Drug List (EDL) which included 307 commonly used pharmaceuticals. These will be subsidized by the government to provide easier access to all citizens. China Yongxin distributes 295 products included on this list and we believe our Company will benefit from the government's efforts to boost domestic spending, in addition to the new healthcare reform which is gaining momentum," commented Mr. Yongxin Liu, Chairman and Chief Executive Officer of China Yongxin. "We have added 12 high margin pharmaceutical products with exclusive distribution rights in Jilin province in the first half of 2009 and we expect this to drive market share gains and growth during the balance of this year."

Cost of goods sold for the second quarter was approximately $11.9 million, yielding a gross profit of $2.7 million and gross margins of 18.6%, compared to $2.9 million in gross profit and a gross margin of 19.6% during the second quarter of 2008. The slight decrease in gross margins was primarily attributable to the slight increase in cost of goods sold.

Operating expenses for the three months ended June 30, 2009, were $1.5 million, compared to approximately $1.6 million in the same period in 2008. Selling expenses for the period decreased marginally to $0.2 million from the year ago period. The Company prudently managed utilities usage, transportation costs and sales people to effectively reduce selling expenses and maintain gross profit. General and administration expenses for the three months ended June 30, 2009 increased approximately 30.7% to $0.8 million, compared to $0.6 million in the same year ago period, with the majority of the increase related to auditing expenses.

Operating income for the second quarter of 2009 totaled approximately $1.2 million, a 9.0% decrease from the $1.3 million reported for the second quarter of 2008. Operating margins were 8.1% and 9.0% for the second quarter of 2009 and 2008, respectively.

For the second quarter of 2009, net income was approximately $1.0 million, a 44.8% increase from the $0.7 million reported during the second quarter of 2008. The increase was primarily related to the absence of a $0.2 million interest expense which occurred during the second quarter of 2008. Diluted earnings per share were $0.03 compared to $0.02 for the second quarter of 2009 and 2008 respectively, based upon 32.0 million and 32.1 million shares. The income tax was $0.5 million compared to $0.6 million in the second quarter of 2008 with an effective tax rate of 28.2% in the second quarter.

Six-Month Results

For the six months ended June 30, 2009, revenues decreased approximately 19.4% to $23.8 million compared to the same period in 2008. Gross profit was $4.9 million for the first six months of 2009, representing a decrease of 8.1% from the first six months of 2008. Gross margins were 20.8% for the first six months of 2009 compared to 18.2% for the same period in 2008.

Income from operations was $1.8 million for the first six months of 2009, representing a decrease of 27.6% over the first six months of 2008. Operating margins were 7.7% for the first six months of 2009 compared to 8.6% for the first six months of 2008. Net income decreased marginally to $1.5 million for the six months ended June 30, 2009 compared to the same period in 2008. Diluted earnings per share were $0.05 compared to $0.05 for the first six months of fiscal 2009 and 2008 respectively, based upon 32.0 million and 32.1 million shares.

Balance Sheet and Cash Flow

Cash and cash equivalents totaled $1.6 million on June 30, 2009, compared to $0.6 million on December 31, 2008, while the Company maintained a short-term loan payable of $2.2 million. Accounts receivable grew 17.2% to $7.1 million from $6.0 million on December 31, 2008. Days sales outstanding stood at 43 compared to 37 in the second quarter of last year. The Company had a current ratio of 1.8 to 1 on June 30, 2009 and stockholders' equity of $19.7 million. For the first six months of 2009, the Company generated $1.0 million in cash from operations versus $2.0 million for the same period in 2008.

Business Development

On March 9, 2009, China Yongxin formally launched its Electronic Diagnosis System. To date the Company has installed 20 systems in Yongxin chain drugstores, all located in Changchun, Jilin. The System enables its customers to remotely receive a medical diagnosis and conveniently purchase prescription drugs at the store. The Company is always working to improve the level of service it offers, and leverage its large and growing base of "Member" customers who are entitled to discounts, rebates and special offers. This strategy, in addition to selling a broader array of higher margin health, beauty and cosmetics products, has increased customer retention and improved revenue and profitability in this business segment.

Since the beginning of 2009, China Yongxin has signed 12 exclusive distribution agreements for Jilin province with several well-known Pharmaceutical Manufacturers including Tianjin Smith Kline & French Laboratones Ltd. As of June 30, 2009, China Yongxin has approximately 216 drugs with exclusive distribution rights in Jilin province. This portfolio is a key component of its long-term growth strategy to leverage the large distribution center and channels established to drive incremental future revenue growth. These agreements are typically one year in duration and renewable.

China Yongxin recently secured loans from local banks and rural credit unions totaling $2.9 million with terms ranging from 1 to 3 years and are renewable after the initial terms. These funds will be utilized to provide working capital for the Company's distribution segment as it capitalizes on new organic growth opportunities supported by the government's new healthcare initiative.

"With enhanced government support, specifically the commencement of China's $126 billion health care reform plan focused on providing a broader spectrum of healthcare services and pharmaceutical products to all Chinese residents, we are confident that our modernized logistic center and distribution channels, broad customer base of chain drugstores, extensive product portfolio, and committed management team will enable us to resume our growth momentum and capitalize on a long-term, secular growth opportunity," concluded Mr. Liu.

About China Yongxin Pharmaceuticals, Inc.

China Yongxin Pharmaceuticals, Inc. was founded in 1993 as the Changchun Yongxin Dirui Medical Co., Ltd. (Yongxin), a wholesale drug distributor. Its products include Chinese traditional medicines, pharmaceutical preparations, natural health products, health food, cosmetics, and medical equipment. It began retail operations in 2004, and in 2005, it gained franchise rights from one of the world's largest drug chains for China's Jilin Province. By the end of 2007, the Company had become one of the fastest growing pharmaceutical companies in China through its retail chain of 93 drug outlets as well as wholesale distribution and manufacturing operations in Northeastern China. For more information about China Yongxin Pharmaceuticals, please visit .

Forward-Looking Statements

This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's periodic reports filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. China Yongxin Pharmaceutical Inc. does not assume any duty to publicly update or revise the material contained herein.

    For more information, please contact:

    For the Company:
     Mr. Sam Liu, COO
     China Yongxin Pharmaceuticals, Inc.
     Tel:   +1-626-581-9098

     Mr. Matthew Hayden, HC International
     Tel:   +1-561-245-5155

                           CONSOLIDATED BALANCE SHEETS
                    AS OF JUNE 30, 2009 AND DECEMBER 31, 2008

                                             June 30, 2009  December 31, 2008
    Current Assets:
    Cash and cash equivalents                   $1,620,168          $609,422
    Accounts receivable, net                     7,070,275         6,030,874
    Notes receivable                             1,561,462         1,334,078
    Other receivable, net                          552,549           356,573
    Advances to suppliers                        8,465,678         6,186,269
    Prepaid expenses                               245,832           345,686
    Inventory, net                               7,923,325         7,864,677
    Current assets of the discontinued
     operations                                         46                46
    Total Current Assets                        27,439,336        22,727,625

    Property and Equipment, net                  2,512,538         2,680,207

    Construction In Progress                     6,357,179         6,066,249

    Intangible Assets, net                          60,428            73,687
    Total Assets                               $36,369,481       $31,547,768


    Current Liabilities:
    Accounts payable                            $5,944,014        $3,255,148
    Accrued expenses & other payable             2,694,603         2,447,067
    Advances from customers                      1,570,322         2,580,894
    Taxes payable                                1,944,665         1,240,411
    Loans to related parties                       184,662           184,662
    Short-term loans payable                     2,221,276         1,967,185
    Deferred income                                186,861           273,753
    Current liabilities of the
     discontinued operations                       628,883           628,883
    Total Current Liabilities                   15,375,288        12,578,003

    Long term loan                               1,318,500         1,320,390

    Commitments and Contingency                         --                --

    Stockholders' Equity:
    Preferred stock, $0.001 par value;
     authorized; 5,000,000 shares issued
     and outstanding                                 5,000             5,000
    Common stock; $0.001 par value;
     authorized; 31,510,540 shares issued
     and outstanding as of June 30, 2009
     and 31,400,540 shares issued and
     outstanding as of December 31, 2008            31,621            31,401
    Additional paid in capital                     635,487           615,906
    Deferred consulting expense -
     issuance of warrants                               --           (72,815)
    Prepaid consulting - issuance of
     shares                                             --           (68,750)
    Receivable from a related party                (50,000)          (50,000)
    Statutory reserve                            2,050,992         1,841,241
    Other comprehensive income                   1,660,196         1,684,649
    Retained earnings                           10,818,845         9,563,803
    Non-controlling interest                     4,523,552         4,098,940
        Total Stockholders' Equity              19,675,693        17,649,375
    Total Liabilities and Stockholders'
     Equity                                    $36,369,481       $31,547,768


                              For the Three-Month       For the Six-Month
                                    Period                    Period
                                 Ended June 30,            Ended June 30,
                               2009         2008         2009         2008
    Net Revenues           $14,638,615  $14,580,500  $23,823,609  $29,574,097
    Cost of Goods Sold     (11,920,027) (11,723,541) (18,874,297) (24,190,231)
    Gross profit             2,718,588    2,856,959    4,949,312    5,383,866

    Operating Expenses:
    Selling expenses           763,290      963,352    1,583,452    1,724,373
    General and
     expenses                  767,160      587,915    1,521,874    1,113,315
    Total operating
     expenses                1,530,449    1,551,267    3,105,325    2,837,688

    Income From Operations   1,188,139    1,305,692    1,843,986    2,546,178

    Other Income
    Other income               706,758      600,205      794,555      834,140
    Other expense              (47,160)     103,634      (20,783)     (34,906)
    Interest income
     (expense)                  16,458     (225,005)       7,984     (227,112)
    Total other income         676,057      478,834      781,757      572,122

    Operating Income
     Before Income Tax and
     Non controlling
     Interest                1,864,196    1,784,526    2,625,743    3,118,300

    Provision for income
     tax                      (525,801)    (565,227)    (730,566)    (940,142)

    Net Income Before Non
     controlling Interest    1,338,394    1,219,299    1,895,177    2,178,158

    Non controlling
     interest                 (297,801)    (500,378)    (430,386)    (691,881)

    Net Income               1,040,594      718,921    1,464,791    1,486,277

    Other Comprehensive
    Foreign exchange
     translation gain          (42,017)     294,872      (18,340)     836,712

    Net Comprehensive
     Income                    998,577    1,013,793    1,446,451    2,322,989

    Earning per share
    Basic                        $0.03        $0.02        $0.05        $0.05
    Diluted                      $0.03        $0.02        $0.05        $0.05
    Weighted average
     number of shares
    Basic                   31,148,219   31,116,845   31,095,623   31,079,138
    Diluted                 32,048,219   32,144,356   31,995,623   32,106,649

             FOR THE SIX MONTH PERIODS ENDED JUNE 30, 2009 AND 2008

                                                   2009              2008
    Net Income attributable to the
     company                                    $1,464,791        $1,486,277
    Adjustments to reconcile net income
     to net cash provided by operating
    Depreciation and amortization                  152,845           167,869
    Stocks and warrants issued or to be
     issued for services                            61,750           141,566
    Amortization of prepaid & deferred
     consulting cost                               141,565
    Non-controlling interest                       430,386           691,881
    (Increase) / decrease in current
    Accounts receivable                         (1,048,523)       (3,183,428)
    Notes receivable                              (229,403)               --
    Other receivable                              (196,580)         (799,159)
    Advances to suppliers                       (2,289,358)        2,077,575
    Prepaid expenses                                99,406           (70,437)
    Inventory                                      (69,939)       (1,556,377)
    Increase / (decrease) in current
    Accounts payable                             1,768,564         1,342,605
    Notes payable                                  552,449                --
    Other payable                                  677,711             2,571
    Accrued expense                               (107,245)               --
    Tax payable                                    706,368           857,194
    Advances from customers                     (1,007,358)        1,047,628
    Deferred revenue                               (86,541)         (249,545)
    Net cash provided by operating
     activities                                  1,020,888         1,956,221

    Proceeds from minority interest
     shareholders                                       --            11,406
    Additions to construction in progress         (275,529)               --
    Purchase of property, equipment and
     intangible assets                                  --        (2,626,220)
    Net cash used in investing activities         (275,529)       (2,614,813)

    Receipt of short term loan                          --         1,964,749
    Receipts of loan from non-related
     parties                                       256,843                --
    Receipts of Loan from related parties               --        (1,620,887)
    Net cash provided by financing
     activities                                    256,843           343,863

     CASH EQUIVALENTS                            1,002,201          (314,730)

     CASH AND CASH EQUIVALENTS                       8,545           225,092

     BALANCE                                       609,422         1,180,029

     BALANCE                                    $1,620,168        $1,090,389

        Interest paid                              $71,126          $101,631
        Income tax paid                            $19,097               $--
    Conversion of account receivable to
     note receivable                                   $--          $841,686

SOURCE China Yongxin Pharmaceuticals, Inc.

SOURCE China Yongxin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017  DarioHealth ... and big data solutions, today announced that its MyDario product is expected ... local TV listings for when The Dr. Oz Show airs in your ... The nine-time Emmy ... ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... been named one of Michigan’s 2017 Best and Brightest in Wellness® by Best ... in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 ...
Breaking Medicine News(10 mins):